# US 2018/0021314 A1 · Therapeutic agent for meibomian dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021314 A1
- Document ID: US20180021314A1
- Status: Published application
- Kind: A1
- Application number: 15/722,257
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2013-03-13
- Assignees: Santen Pharmaceutical Co., Ltd.
- Applicants: Santen Pharmaceutical Co., Ltd.
- Inventors: Hideki MIYAKE; Tomoko ODA; Daisuke SHII
- Web page: https://patentgrep.com/patent/US20180021314A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.

## Claims

### Claim 1

A method for treatment of meibomian gland dysfunction in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the eye drop comprises 0.5% (w/v) of sirolimus.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the eye drop is administered to the eyes of the mammalian subject 1 time per day.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the eye drop is a suspension or an emulsion.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the eye drop is a suspension.

### Claim 6 (depends on 1)

The method according to claim 1, wherein eye drop is a suspension and comprises 0.5% (w/v) of sirolimus.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the eye drop is administered to the eyes of the mammalian subject 1 time per day.
